Table 1 Comparison of baseline measurements between the two groups.

Age [years]

34.9

34.4

0.6812

 95% CI

(33.0 — 36.8)

(32.4 — 36.3)

Weight [kg]

65.8

68.1

0.6261

 95% CI

(58.3 — 73.3)

(62.2 — 74.1)

BMI [kg/m²]‡

22.4^†

23.1^†

0.8513

 95% CI

(19.3 — 27.0)

(19.9 — 26.3)

Muscle mass [kg]^‡

44.5^†

45.5^†

0.5329

 95% CI

(40.2 — 49.2)

(43.1 — 48.3)

Fat mass [kg]^‡

14.7^†

19.5^†

0.4364

 95% CI

(10.8 — 23.9)

(12.8 — 24.8)

Grip strength [kg]

 Affected side

29.1

32.1

0.0630

  95% CI

(27.1 — 31.2)

(29.6 — 34.6)

 Unaffected side^‡

30.5^†

33.1^†

0.0621

  95% CI

(24.5 — 33.5)

(29.1 — 38.0)

Tumour profile

 T1

3(15.79)

3(14.29)

> 0.9999

 T2

10(52.63)

12(57.14)

 T3

6(31.58)

5(23.81)

 T4

0(0)

1(4.76)

 N0

11(57.89)

14(66.67)

0.5801

 N+

6(31.58)

6(28.57)

 N2

2(10.53)

1(4.76)

Therapy

 Doxorubicin

21(100)

19(100)

N/A

 Paclitaxel

15(78.95)

16(76.19)

0.5568

 Carboplatin

6(31.58)

5(23.81)

0.8454

 Trastuzumab

8(42.11)

11(52.38)

0.3497

 Docetaxel

3(15.79)

2(9.52)

0.9047

 Pertuzumab

2(10.53)

3(14.29)

0.9047

 Epirubicin

0(0.00)

1(4.76)

0.9596

 Cyclophosphamide

0(0.00)

1(4.76)

0.9596